Preceding Data order Lipitor now
New Results are Formed in Preceding Data that Lipitor - Single Statin to Show Influence in Head-To-Head, representing itself Test
Separate Analysis Shows, Buy Lipitor Cuts Risk Coronary Event on Repeated Stroke Patient
NEW ORLEANS-(Promarshiruyte 26, 2007) - Viagra said today, which comes of two new imagings of the test shown that more high dose Lipitor stopped the passing атеросклероза on patient with coronary heart disease or household hypercholesterolemia (FH). Test, which were intended to research efficiency former investigational composition torcetrapib in combinations with Lipitor in contrast with Lipitor only, introduced today on annual meeting of the American College to Cardiologies.
In lever (the hand) Lipitor ILLUSTRATIONS and GLOWS 1 test, patients took the average dose Lipitor 23 mg. and 56 mg. accordingly and experienced halting passings атеросклероза. In test the ILLUSTRATIONS, the processing regression plates ended with Lipitor in the most sick part of coronary artery. On contrast in lever (the hand) Lipitor GLOWS 2 patients took the low average dose Lipitor 13 mg. and passing was.
“From clinical prospect that remarkable in these study - that Lipitor was capable to stop the passing a disease, including most it is difficult to process the patient FH studied in GLOW 1,” said Professor John Kastelein, leaden investigator for two from test, and professor medicine and chairman vascular medicine in University Medical Centre in Amsterdam. “These test are formed on effect visible Lipitor on multiple imaging the test.”
Lipitor - single statin studied in head-to-head visualize test. In AT EARLIEST CONVENIENCE and test the ARBITRATOR, which measured the changes to cIMT, high risk patient, which took mg Lipitor 80 felt the regression in атеросклерозе in contrast with patient, which took other statins. In test the CHANGE, the patients Lipitor felt the halting passings of the plate in contrast with pravastatin, and patients Lipitor felt the significant reduction in volume of the plate in the most sick segment in contrast with pravastatin as it is measured IVUS.
According to Dr Michael Berelowitz, the Senior Vice President of the global medical fission Pfizer’s, “These results support the preceding studies where more high doses Lipitor have demonstrated the influence in. However, visualizing information, scientifically interesting, we know that physicians will take the clinical decisions was founded in proved heartily result.”
